IP Library › Assignment 037656/0777
Patent Assignment
Reel/Frame 037656/0777

Security Interest

Recorded: 2016-02-03 Pages: 9
Assignor
Assignee
CIT BANK, N.A., AS COLLATERAL AGENT
11 WEST 42ND STREET, NEW YORK, NEW YORK, 10036
Covered Properties (26)
Combined diffusion/osmotic pumping drug delivery system
Patent: 6,352,721 →
Application: 09/483,282 →
Osmotic Device Containing Pseudoephedrine and an H1ANTAGONIST
Patent: 6,613,357 →
Application: 09/725,655 →
Publication: US 2002/0102305
Osmotic Device Containing Venlafaxine and an Anti-Psychotic Agent
Patent: 6,572,890 →
Application: 09/728,276 →
Publication: US 2001/0048943
Osmotic Device Having a Preformed Passageway That Increases in Size
Patent: 6,599,284 →
Application: 09/728,859 →
Publication: US 2002/0099361
Osmotic Device Within an Osmotic Device
Patent: 6,491,949 →
Application: 09/755,827 →
Publication: US 2002/0035357
Drug Delivery Device Containing Oseltamivir and an H1 Antagonist
Patent: 6,605,302 →
Application: 09/907,486 →
Publication: US 2003/0044457
Multi-Layered Osmotic Device
Patent: 39,069 →
Application: 10/004,772 →
Combined Diffusion / Osmotic Pumping Drug Delivery System
Patent: 6,753,011 →
Application: 10/047,915 →
Publication: US 2002/0132005
Laser Drilling System and Method
Patent: 6,809,288 →
Application: 10/153,226 →
Publication: US 2003/0189030
Osmotic Device Containing Venlafaxine and an Anti-Psychotic Agent
Patent: 7,008,641 →
Application: 10/377,173 →
Publication: US 2003/0219483
Drug Delivery Device Containing Neuraminidase Inhibitor and an H1 Antagonist
Patent: 7,208,176 →
Application: 10/619,720 →
Publication: US 2004/0062801
Osmotic Device Containing Pseudoephedrine and an H1 Antagonist
Patent: 7,147,870 →
Application: 10/643,011 →
Publication: US 2004/0131685
Rupturing Controlled Release Device Having a Preformed Passageway
Patent: 8,029,822 →
Application: 10/851,866 →
Publication: US 2005/0008702
Laser Drilling System and Method
Patent: 7,569,794 →
Application: 10/957,428 →
Publication: US 2005/0145605
Osmotic Device Containing a Venlafaxine Salt and a Salt Having an Ion in Common
Patent: 8,293,799 →
Application: 11/010,829 →
Publication: US 2005/0163851
Osmotic Device Containing Amantadine and an Osmotic Salt
Patent: 8,252,331 →
Application: 11/287,882 →
Publication: US 2006/0159763
Dual Controlled Release Osmotic Device
Patent: 8,241,667 →
Application: 11/321,736 →
Publication: US 2006/0177510
Dual Controlled Release Dosage Form
Patent: 8,329,217 →
Application: 11/355,315 →
Publication: US 2006/0204578
Triple Combination Release Multi-Layered Tablet
Patent: 8,685,451 →
Application: 12/141,677 →
Publication: US 2008/0299197
Rupturing Controlled Release Device Comprising a Subcoat
Patent: 8,637,080 →
Application: 12/146,069 →
Publication: US 2009/0004229
Osmotic Device Containing Amantadine and an Osmotic Salt
Patent: 8,574,626 →
Application: 13/551,755 →
Publication: US 2013/0115249
Dual Controlled Release Dosage Form
Patent: 8,591,947 →
Application: 13/625,658 →
Publication: US 2013/0108693
Triple Combination Release Multi-layered Tablet
Patent: 9,833,412 →
Application: 14/188,150 →
Publication: US 2014/0302141
Method of Administering Drug
Application: 62/118,910 →
Method of Improving GABA-B Receptor Agonist Therapy
Application: 62/119,017 →
Controlled Release Dosage Form with Enhanced Pharmacokinetics
Application: 62/131,495 →
Related Assignments (12)
Other recorded transfers of the patents in this record — the chain of ownership.
Transfer of Right to Make, Use, Sell, Offer to Sell for Nifedipine Feb 4, 2010
From: OSMOTICA CORP.
To: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
Reel/Frame 023892/0674 →
Transfer of Right to Make, Use, Sell, Offer to Sell for Oxybutynin Feb 4, 2010
From: OSMOTICA CORP.
To: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
Reel/Frame 023892/0723 →
Corrective Assignment to Correct the Name of the Assignee on the Recordation Sheet to Osmotica Pharmaceutical Corp. Previously Recorded on Reel 023892 Frame 0674. Assignor(S) Hereby Confirms the Transfer of Right to Make, Use, Sell, Offer to Sell for Nifedipine. Feb 8, 2010
From: OSMOTICA CORP.
To: OSMOTICA PHARMACEUTICAL CORP.
Reel/Frame 023905/0766 →
Corrective Assignment to Correct the Name of the Assignee on the Recordation Sheet to Osmotica Pharmaceutical Corp. Previously Recorded on Reel 023892 Frame 0723. Assignor(S) Hereby Confirms the Transfer of Right to Make, Use, Sell, Offer to Sell for Oxybutynin. Feb 8, 2010
From: OSMOTICA CORP.
To: OSMOTICA PHARMACEUTICAL CORP.
Reel/Frame 023905/0752 →
Assignment of Assignor's Interest Apr 29, 2011
From: OSMOTICA HOLDINGS CORP. A.V.V.
To: OSMOTICA (CYPRUS) LIMITED
Reel/Frame 026202/0710 →
Assignment of Assignor's Interest Apr 29, 2011
From: OSMOTICA CORP.
To: OSMOTICA HOLDINGS CORP. A.V.V.
Reel/Frame 026202/0244 →
Assignment of Assignor's Interest Apr 29, 2011
From: OSMOTICA (CYPRUS) LIMITED
To: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
Reel/Frame 026202/0506 →
Assignee Change of Address Nov 20, 2013
From: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
To: OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
Reel/Frame 031692/0741 →
Change of Address for Assignee Jul 2, 2020
From: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KFT
To: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KFT
Reel/Frame 053122/0081 →
Security Interest Aug 27, 2021
From: AVION PHARMACEUTICALS, LLC; SOVEREIGN PHARMACEUTICALS, LLC; ACELLA HOLDINGS, LLC
To: CIBC BANK USA, AS ADMINISTRATIVE AGENT
Reel/Frame 057310/0385 →
Release of Security Interest Aug 28, 2021
From: CIT BANK, N.A., AS COLLATERAL AGENT
To: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KORLÁTOLT FELELOSSÉGU TÁRSASÁG
Reel/Frame 057319/0873 →
Assignment of Assignor's Interest Sep 28, 2021
From: OSMOTICA KERESKEDELMI ÉS SZOLGÁLTATÓ KORLÁTOLT FELELOSSÉGU TÁRSASÁG
To: ACELLA HOLDINGS, LLC
Reel/Frame 057627/0758 →